Abstract:Background Prevalence of cardiovascular disease risk factors and rates of atherosclerotic cardiovascular disease outcomes vary across racial/ethnic groups. This analysis examined the effects of evolocumab on LDL‐C (low‐density lipoprotein cholesterol) levels and LDL‐C goals achievement by race/ethnicity. Methods and Results Data from 15 phase 2 and 3 studies of treatment with evolocumab versus placebo or ezetimibe were pooled (n=7669). Results were analyzed by participant clinical characteristics and by self‐identified race/ethnicity. Key outcomes included percent change from baseline in LDL‐C, achievement of LDL‐C <70 mg/dL, and LDL‐C reduction of ≥50% at 12 weeks and at 1 to 5 years. Across 12‐week studies, mean percent change in LDL‐C from baseline in evolocumab‐treated participants was −52% to −59% for White and −46% to −67% for non‐White participants, across clinical characteristics groups. LDL‐C <70 mg/dL was achieved in 43% to 84% and 62% to 94% and LDL‐C reduction of ≥50% in 63% to 78% and 58% to 86%, respectively. In 1‐ to 5‐year studies, mean percent change in LDL‐C was −46% to −52% for White and −49% to −55% for non‐White participants. LDL‐C <70 mg/dL was achieved in 53% to 84% and 66% to 77%, and LDL‐C reduction of ≥50% in 53% to 67% and 58% to 68%, respectively. The treatment effect on mean percent change in LDL‐C differed only in participants with type 2 diabetes mellitus, with a larger reduction in Asian participants. The qualitative interaction P values were nonsignificant, indicating consistent directionality of effect. Conclusions Similar reduction in LDL‐C levels with evolocumab was observed across racial/ethnic groups in 12‐week and 1‐ to 5‐year studies. Among those with diabetes mellitus, Asian participants had greater LDL‐C reduction. Nonstandard Abbreviations and Acronyms PCSK9 proprotein convertase subtilisin/kexin type 9 Q2W every 2 weeks (dosing regimen) QM once monthly (dosing regimen) Clinical Perspective What Is New? Lipid‐lowering therapy with evolocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, substantially reduces LDL‐C (low‐density lipoprotein cholesterol) in patients with a broad range of clinical characteristics. In this pooled analysis, evolocumab therapy was associated with similar reductions in LDL‐C across racial/ethnic groups in both 12‐week and 1‐ to 5‐year studies (eg, in 12‐week studies, mean percent change in LDL‐C from baseline in evolocumab‐treated participants was −52% to −59% for White and −46% to −67% for non‐White participants across clinical characteristic groups, and LDL‐C <70 mg/dL was achieved in 43–84% and 62–94%, respectively). Among those with diabetes mellitus, Asian participants had greater reduction in LDL‐C. What Are the Clinical Implications? These findings provide further evidence for the use of evolocumab therapy to lower LDL‐C in individuals of diverse racial/ethnic backgrounds, including those with diabetes mellitus. Prevalence of major cardiovascular disease (CVD) risk factors and rates of CVD outcomes vary markedly by race and ethnicity. 1 , 2 Non‐Hispanic Black participants experience higher age‐adjusted rates of stroke and mortality because of CVD, and higher rates of major CVD comorbid conditions compared with non‐Hispanic White participants. 1 , 3 Rates of elevated total cholesterol and LDL‐C (low‐density lipoprotein cholesterol) levels vary by race/ethnicity (ie, rates are higher in Hispanic men compared with non‐Hispanic White men), while prevalence of elevated LDL‐C level in non‐Hispanic Black men is similar to that among non‐Hispanic White men. 1 Non‐Hispanic White women have the highest rates of elevated total cholesterol and LDL‐C levels. 1 The burden of low HDL‐C (high‐density lipoprotein cholesterol)/high triglyceride dyslipidemia appears greater in -Abstract Truncated-

Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study

Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease

A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Asia-Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study

Prevalence, incidence, and treatment of dyslipidemia in patients with high or very high cardiovascular risk in Germany

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome

A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence

Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events

Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and not treating with lipoprotein apheresis

Global burden of high-risk cardiovascular patients without prior myocardial infarction or stroke: VESALIUS-REAL - preliminary results from Germany

Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies.

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of Evolocumab in Healthy Chinese Subjects

Real-World Application of Evolocumab Among Patients with Hyperlipidemia in Korea: A Multicenter Prospective Study

Evaluating the Effectiveness and Safety of Evinacumab in Treating Hypercholesterolemia and Hypertriglyceridemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies